Horizon Kinetics Asset Management LLC cut its stake in Danaher Co. (NYSE:DHR – Free Report) by 24.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 6,678 shares of the conglomerate’s stock after selling 2,193 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in Danaher were worth $1,533,000 at the end of the most recent quarter.
A number of other institutional investors also recently bought and sold shares of the stock. Gilbert & Cook Inc. increased its stake in Danaher by 2.5% in the fourth quarter. Gilbert & Cook Inc. now owns 1,749 shares of the conglomerate’s stock worth $401,000 after purchasing an additional 42 shares during the period. Grimes & Company Inc. increased its stake in Danaher by 0.6% in the fourth quarter. Grimes & Company Inc. now owns 7,390 shares of the conglomerate’s stock worth $1,696,000 after purchasing an additional 43 shares during the period. Dakota Community Bank & Trust NA increased its stake in Danaher by 16.4% in the fourth quarter. Dakota Community Bank & Trust NA now owns 320 shares of the conglomerate’s stock worth $73,000 after purchasing an additional 45 shares during the period. Howard Capital Management Group LLC increased its stake in Danaher by 4.1% in the third quarter. Howard Capital Management Group LLC now owns 1,229 shares of the conglomerate’s stock worth $342,000 after purchasing an additional 48 shares during the period. Finally, Wrapmanager Inc. increased its stake in Danaher by 3.1% in the third quarter. Wrapmanager Inc. now owns 1,659 shares of the conglomerate’s stock worth $461,000 after purchasing an additional 50 shares during the period. 79.05% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 11.10% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on Danaher
Danaher Trading Up 1.0 %
Danaher stock opened at $212.78 on Tuesday. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 52 week low of $196.80 and a 52 week high of $281.70. The company has a market capitalization of $152.08 billion, a price-to-earnings ratio of 40.30, a price-to-earnings-growth ratio of 2.66 and a beta of 0.82. The stock has a 50-day moving average price of $219.57 and a 200 day moving average price of $240.07.
Danaher (NYSE:DHR – Get Free Report) last released its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the prior year, the business earned $2.09 earnings per share. Sell-side analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.
Danaher Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be issued a dividend of $0.32 per share. This is an increase from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.60%. Danaher’s payout ratio is 24.24%.
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Stories
- Five stocks we like better than Danaher
- What is the Australian Securities Exchange (ASX)
- Can TikTok Stock Picks Really Make You Rich?
- What Makes a Stock a Good Dividend Stock?
- The “Quality” Rotation: Back to Basics Investing
- When to Sell a Stock for Profit or Loss
- Occidental Petroleum: 4 Reasons to Love These Prices
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.